60 Degrees Pharmaceuticals (SXTP) Asset Writedowns and Impairment (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly Asset Writedowns and Impairment of -$251677.0 for Q1 2026, down 1134.19% quarter-over-quarter from -$20392.0 in Q4 2023.
60 Degrees Pharmaceuticals (SXTP) Asset Writedowns and Impairment (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported Asset Writedowns and Impairment for 3 consecutive years, with -$251677.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Asset Writedowns and Impairment changed N/A year-over-year to -$251677.0; the TTM figure through Mar 2026 stood at -$416220.0 (changed N/A YoY), while the FY2023 annual figure was -$160338.0, down 131.77% from the prior year.
- Asset Writedowns and Impairment slipped to -$251677.0 in Q1 2026 per SXTP's latest filing, from -$20392.0 in the prior quarter.
- Across five years, Asset Writedowns and Impairment topped out at $427969.0 in Q3 2022 and bottomed at -$251677.0 in Q1 2026.
- Historically, Asset Writedowns and Impairment has averaged $2659.0 across 3 years, with a median of -$8093.5 in 2023.
- On a YoY basis, Asset Writedowns and Impairment climbed as much as 144.92% in 2023 and fell as far as 144.92% in 2023.
- 60 Degrees Pharmaceuticals' Asset Writedowns and Impairment stood at $427969.0 in 2022, then slumped by 104.76% to -$20392.0 in 2023, then plunged by 1134.19% to -$251677.0 in 2026.
- Business Quant data shows SXTP's Asset Writedowns and Impairment at -$251677.0 in Q1 2026, -$20392.0 in Q4 2023, and -$192247.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -251,677.00 |
| Mar 31, 2026 | -251,677.00 |
| Dec 31, 2023 | -20,392.00 |
| Dec 31, 2023 | -20,392.00 |
| Sep 30, 2023 | -192,247.00 |
| Sep 30, 2023 | -192,247.00 |
| Jun 30, 2023 | 48,096.00 |
| Jun 30, 2023 | 48,096.00 |
| Mar 31, 2023 | 4,205.00 |
| Mar 31, 2023 | 4,205.00 |
| Sep 30, 2022 | 427,969.00 |
| Sep 30, 2022 | 427,969.00 |